Details for New Drug Application (NDA): 209920
✉ Email this page to a colleague
The generic ingredient in LUBIPROSTONE is lubiprostone. There are ten drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the lubiprostone profile page.
Summary for 209920
Tradename: | LUBIPROSTONE |
Applicant: | Teva Pharms Usa Inc |
Ingredient: | lubiprostone |
Patents: | 0 |
Pharmacology for NDA: 209920
Mechanism of Action | Chloride Channel Activators |
Medical Subject Heading (MeSH) Categories for 209920
Suppliers and Packaging for NDA: 209920
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 209920 | ANDA | Teva Pharmaceuticals, Inc. | 0480-3479 | 0480-3479-06 | 60 CAPSULE, GELATIN COATED in 1 BOTTLE (0480-3479-06) |
LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 209920 | ANDA | Teva Pharmaceuticals, Inc. | 0480-4138 | 0480-4138-06 | 60 CAPSULE, GELATIN COATED in 1 BOTTLE (0480-4138-06) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 8MCG | ||||
Approval Date: | Jan 18, 2022 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 24MCG | ||||
Approval Date: | Jan 18, 2022 | TE: | AB | RLD: | No |
Complete Access Available with Subscription